Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACACB | O00763 | 10/20 | 0.46 |
| ▸ | ACACA | Q13085 | 5/20 | 0.46 |
| ▸ | PLA2G4B | P0C869 | 3/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20372470 | 0.89 | ACACB (0.46) | ACACBACACAPLA2G4BHPGDLMNA | |
| SCHEMBL24654315 | 0.88 | ACACB (0.44) | ACACBACACAHPGDLMNASLC2A1 | |
| SCHEMBL21341632 | 0.88 | ACACB (0.46) | ACACBACACAPLA2G4BHPGDLMNA | |
| SCHEMBL21025835 | 0.85 | ACACB (0.44) | ACACBACACAPLA2G4BHPGDLMNA | |
| SCHEMBL21664495 | 0.80 | PLA2G4B (0.44) | ACACBPLA2G4BLMNA | |
| SCHEMBL21214833 | 0.79 | PLA2G4B (0.44) | ACACBPLA2G4B | |
| SCHEMBL23350266 | 0.79 | PLA2G4B (0.44) | ACACBPLA2G4B | |
| SCHEMBL20331331 | 0.79 | PLA2G4B (0.46) | PLA2G4B | |
| SCHEMBL20234740 | 0.79 | PLA2G4B (0.46) | PLA2G4B | |
| SCHEMBL22151313 | 0.78 | PLA2G4B (0.48) | PLA2G4B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12036209-B2 | Compounds and methods for the targeted degradation of Interleukin-1 receptor-associated kinase 4 polypeptides | ARVINAS OPERATIONS, INC. (US) | 2024-07-16 | — | — | US | disclosed |
| US-20220402907-A1 | MODULATORS OF PROTEOLYSIS AND ASSOCIATED METHODS OF USE | YALE UNIVERSITY | 2022-12-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12036209-B2 | Compounds and methods for the targeted degradation of Interleukin-1 receptor-associated kinase 4 polypeptides | IRAK1, IRAK4, IRAK2 | ACACB 3092/4885ACACA 2745/4885PLA2G4B 2192/4885 |
| US-20220402907-A1 | MODULATORS OF PROTEOLYSIS AND ASSOCIATED METHODS OF USE | MDM2, CRBN, VHL | ACACB 2262/4885ACACA 3487/4885PLA2G4B 935/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.